<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:50:31 -0700</creation_date>
  <update_date>2013-05-27 10:58:05 -0600</update_date>
  <accession>HMDBP00524</accession>
  <secondary_accessions>
    <accession>5772</accession>
    <accession>HMDBP06048</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>AChE</synonym>
  </synonyms>
  <gene_name>ACHE</gene_name>
  <general_function>Involved in carboxylesterase activity</general_function>
  <specific_function>Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
</specific_function>
  <pathways>
    <pathway>
      <name>Phospholipid Biosynthesis</name>
      <smpdb_id>SMP00025</smpdb_id>
      <kegg_map_id>map00564</kegg_map_id>
    </pathway>
    <pathway>
      <name>Glycerophospholipid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00564</kegg_map_id>
    </pathway>
    <pathway>
      <name>Cholinergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04725</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00042</accession>
      <name>Acetic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00097</accession>
      <name>Choline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00895</accession>
      <name>Acetylcholine </name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05041</accession>
      <name>Donepezil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14526</accession>
      <name>Tacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14626</accession>
      <name>Gallamine Triethiodide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14685</accession>
      <name>Pyridostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14812</accession>
      <name>Galantamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14815</accession>
      <name>Isoflurophate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14871</accession>
      <name>Pralidoxime</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14943</accession>
      <name>Minaprine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13958</accession>
      <name>5-O-Desmethyldonepezil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15079</accession>
      <name>Demecarium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15116</accession>
      <name>Physostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15124</accession>
      <name>Rivastigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15145</accession>
      <name>Edrophonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15254</accession>
      <name>Ambenonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15330</accession>
      <name>Tubocurarine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15375</accession>
      <name>Decamethonium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15451</accession>
      <name>Ephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15472</accession>
      <name>Neostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00174</accession>
      <name>L-Fucose</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>cholinesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on ester bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carboxylesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>anchored to membrane</description>
      <go_id>GO:0031225</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>axon</description>
      <go_id>GO:0030424</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>basal lamina</description>
      <go_id>GO:0005605</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cell junction</description>
      <go_id>GO:0030054</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cell surface</description>
      <go_id>GO:0009986</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>dendrite</description>
      <go_id>GO:0030425</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum lumen</description>
      <go_id>GO:0005788</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>extracellular space</description>
      <go_id>GO:0005615</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>Golgi apparatus</description>
      <go_id>GO:0005794</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuromuscular junction</description>
      <go_id>GO:0031594</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleus</description>
      <go_id>GO:0005634</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>perinuclear region of cytoplasm</description>
      <go_id>GO:0048471</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>plasma membrane</description>
      <go_id>GO:0005886</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>postsynaptic membrane</description>
      <go_id>GO:0045211</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>presynaptic membrane</description>
      <go_id>GO:0042734</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>synaptic cleft</description>
      <go_id>GO:0043083</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>acetylcholine binding</description>
      <go_id>GO:0042166</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>acetylcholinesterase activity</description>
      <go_id>GO:0003990</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>beta-amyloid binding</description>
      <go_id>GO:0001540</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>carboxylesterase activity</description>
      <go_id>GO:0004091</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>collagen binding</description>
      <go_id>GO:0005518</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>laminin binding</description>
      <go_id>GO:0043236</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>protein homodimerization activity</description>
      <go_id>GO:0042803</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>serine hydrolase activity</description>
      <go_id>GO:0017171</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>acetylcholine catabolic process in synaptic cleft</description>
      <go_id>GO:0001507</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>amyloid precursor protein metabolic process</description>
      <go_id>GO:0042982</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell adhesion</description>
      <go_id>GO:0007155</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell proliferation</description>
      <go_id>GO:0008283</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>choline metabolic process</description>
      <go_id>GO:0019695</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>DNA replication</description>
      <go_id>GO:0006260</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>muscle organ development</description>
      <go_id>GO:0007517</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of synaptic transmission, cholinergic</description>
      <go_id>GO:0032223</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter biosynthetic process</description>
      <go_id>GO:0042136</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter receptor biosynthetic process</description>
      <go_id>GO:0045212</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>osteoblast development</description>
      <go_id>GO:0002076</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phosphatidylcholine biosynthetic process</description>
      <go_id>GO:0006656</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of protein secretion</description>
      <go_id>GO:0050714</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>protein tetramerization</description>
      <go_id>GO:0051262</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>receptor internalization</description>
      <go_id>GO:0031623</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of axonogenesis</description>
      <go_id>GO:0050770</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of dendrite morphogenesis</description>
      <go_id>GO:0048814</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of receptor recycling</description>
      <go_id>GO:0001919</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to wounding</description>
      <go_id>GO:0009611</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>retina development in camera-type eye</description>
      <go_id>GO:0060041</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>synapse assembly</description>
      <go_id>GO:0007416</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Isoform H:Cell membrane</subcellular_location>
    <subcellular_location>Lipid-anchor</subcellular_location>
    <subcellular_location>GPI- anchor</subcellular_location>
    <subcellular_location>Extracellular side</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>7</chromosome_location>
    <locus>7q22</locus>
    <gene_sequence>&gt;1845 bp
ATGAGGCCCCCGCAGTGTCTGCTGCACACGCCTTCCCTGGCTTCCCCACTCCTTCTCCTC
CTCCTCTGGCTCCTGGGTGGAGGAGTGGGGGCTGAGGGCCGGGAGGATGCAGAGCTGCTG
GTGACGGTGCGTGGGGGCCGGCTGCGGGGCATTCGCCTGAAGACCCCCGGGGGCCCTGTC
TCTGCTTTCCTGGGCATCCCCTTTGCGGAGCCACCCATGGGACCCCGTCGCTTTCTGCCA
CCGGAGCCCAAGCAGCCTTGGTCAGGGGTGGTAGACGCTACAACCTTCCAGAGTGTCTGC
TACCAATATGTGGACACCCTATACCCAGGTTTTGAGGGCACCGAGATGTGGAACCCCAAC
CGTGAGCTGAGCGAGGACTGCCTGTACCTCAACGTGTGGACACCATACCCCCGGCCTACA
TCCCCCACCCCTGTCCTCGTCTGGATCTATGGGGGTGGCTTCTACAGTGGGGCCTCCTCC
TTGGACGTGTACGATGGCCGCTTCTTGGTACAGGCCGAGAGGACTGTGCTGGTGTCCATG
AACTACCGGGTGGGAGCCTTTGGCTTCCTGGCCCTGCCGGGGAGCCGAGAGGCCCCGGGC
AATGTGGGTCTCCTGGATCAGAGGCTGGCCCTGCAGTGGGTGCAGGAGAACGTGGCAGCC
TTCGGGGGTGACCCGACATCAGTGACGCTGTTTGGGGAGAGCGCGGGAGCCGCCTCGGTG
GGCATGCACCTGCTGTCCCCGCCCAGCCGGGGCCTGTTCCACAGGGCCGTGCTGCAGAGC
GGTGCCCCCAATGGACCCTGGGCCACGGTGGGCATGGGAGAGGCCCGTCGCAGGGCCACG
CAGCTGGCCCACCTTGTGGGCTGTCCTCCAGGCGGCACTGGTGGGAATGACACAGAGCTG
GTAGCCTGCCTTCGGACACGACCAGCGCAGGTCCTGGTGAACCACGAATGGCACGTGCTG
CCTCAAGAAAGCGTCTTCCGGTTCTCCTTCGTGCCTGTGGTAGATGGAGACTTCCTCAGT
GACACCCCAGAGGCCCTCATCAACGCGGGAGACTTCCACGGCCTGCAGGTGCTGGTGGGT
GTGGTGAAGGATGAGGGCTCGTATTTTCTGGTTTACGGGGCCCCAGGCTTCAGCAAAGAC
AACGAGTCTCTCATCAGCCGGGCCGAGTTCCTGGCCGGGGTGCGGGTCGGGGTTCCCCAG
GTAAGTGACCTGGCAGCCGAGGCTGTGGTCCTGCATTACACAGACTGGCTGCATCCCGAG
GACCCGGCACGCCTGAGGGAGGCCCTGAGCGATGTGGTGGGCGACCACAATGTCGTGTGC
CCCGTGGCCCAGCTGGCTGGGCGACTGGCTGCCCAGGGTGCCCGGGTCTACGCCTACGTC
TTTGAACACCGTGCTTCCACGCTCTCCTGGCCCCTGTGGATGGGGGTGCCCCACGGCTAC
GAGATCGAGTTCATCTTTGGGATCCCCCTGGACCCCTCTCGAAACTACACGGCAGAGGAG
AAAATCTTCGCCCAGCGACTGATGCGATACTGGGCCAACTTTGCCCGCACAGGGGATCCC
AATGAGCCCCGAGACCCCAAGGCCCCACAATGGCCCCCGTACACGGCGGGGGCTCAGCAG
TACGTTAGTCTGGACCTGCGGCCGCTGGAGGTGCGGCGGGGGCTGCGCGCCCAGGCCTGC
GCCTTCTGGAACCGCTTCCTCCCCAAATTGCTCAGCGCCACCGACACGCTCGACGAGGCG
GAGCGCCAGTGGAAGGCCGAGTTCCACCGCTGGAGCTCCTACATGGTGCACTGGAAGAAC
CAGTTCGACCACTACAGCAAGCAGGATCGCTGCTCAGACCTGTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>614</residue_number>
    <molecular_weight>67795.525</molecular_weight>
    <theoretical_pi>6.291</theoretical_pi>
    <pfams>
      <pfam>
        <name>AChE_tetra</name>
        <pfam_id>PF08674</pfam_id>
      </pfam>
      <pfam>
        <name>COesterase</name>
        <pfam_id>PF00135</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Acetylcholinesterase
MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV
SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN
RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM
NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV
GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL
VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG
VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE
DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY
EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ
YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN
QFDHYSKQDRCSDL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>177975</genbank_protein_id>
  <uniprot_id>P22303</uniprot_id>
  <uniprot_name>ACES_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1B41</pdb_id>
    <pdb_id>1F8U</pdb_id>
    <pdb_id>1PUV</pdb_id>
    <pdb_id>1PUW</pdb_id>
    <pdb_id>1VZJ</pdb_id>
    <pdb_id>2CLJ</pdb_id>
    <pdb_id>2X8B</pdb_id>
    <pdb_id>3LII</pdb_id>
    <pdb_id>4EY4</pdb_id>
    <pdb_id>4EY5</pdb_id>
    <pdb_id>4EY6</pdb_id>
    <pdb_id>4EY7</pdb_id>
    <pdb_id>4EY8</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M55040</genbank_gene_id>
  <genecard_id>ACHE</genecard_id>
  <geneatlas_id>ACHE</geneatlas_id>
  <hgnc_id>HGNC:108</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Soreq H, Ben-Aziz R, Prody CA, Seidman S, Gnatt A, Neville L, Lieman-Hurwitz J, Lev-Lehman E, Ginzberg D, Lipidot-Lifson Y, et al.: Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G + C-rich attenuating structure. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9688-92.</reference_text>
      <pubmed_id>2263619</pubmed_id>
    </reference>
    <reference>
      <reference_text>Karpel R, Ben Aziz-Aloya R, Sternfeld M, Ehrlich G, Ginzberg D, Tarroni P, Clementi F, Zakut H, Soreq H: Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp Cell Res. 1994 Feb;210(2):268-77.</reference_text>
      <pubmed_id>8299725</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7.  Nature. 2003 Jul 10;424(6945):157-64.</reference_text>
      <pubmed_id>12853948</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wilson MD, Riemer C, Martindale DW, Schnupf P, Boright AP, Cheung TL, Hardy DM, Schwartz S, Scherer SW, Tsui LC, Miller W, Koop BF: Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res. 2001 Mar 15;29(6):1352-65.</reference_text>
      <pubmed_id>11239002</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chhajlani V, Derr D, Earles B, Schmell E, August T: Purification and partial amino acid sequence analysis of human erythrocyte acetylcholinesterase. FEBS Lett. 1989 Apr 24;247(2):279-82.</reference_text>
      <pubmed_id>2714437</pubmed_id>
    </reference>
    <reference>
      <reference_text>Velan B, Grosfeld H, Kronman C, Leitner M, Gozes Y, Lazar A, Flashner Y, Marcus D, Cohen S, Shafferman A: The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem. 1991 Dec 15;266(35):23977-84.</reference_text>
      <pubmed_id>1748670</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shafferman A, Kronman C, Flashner Y, Leitner M, Grosfeld H, Ordentlich A, Gozes Y, Cohen S, Ariel N, Barak D, et al.: Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem. 1992 Sep 5;267(25):17640-8.</reference_text>
      <pubmed_id>1517212</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yang L, He HY, Zhang XJ: Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells. Neurosci Res. 2002 Apr;42(4):261-8.</reference_text>
      <pubmed_id>11985878</pubmed_id>
    </reference>
    <reference>
      <reference_text>Felder CE, Botti SA, Lifson S, Silman I, Sussman JL: External and internal electrostatic potentials of cholinesterase models.  J Mol Graph Model. 1997 Oct;15(5):318-27, 335-7.</reference_text>
      <pubmed_id>9640563</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kryger G, Harel M, Giles K, Toker L, Velan B, Lazar A, Kronman C, Barak D, Ariel N, Shafferman A, Silman I, Sussman JL: Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1385-94.</reference_text>
      <pubmed_id>11053835</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dvir H, Harel M, Bon S, Liu WQ, Vidal M, Garbay C, Sussman JL, Massoulie J, Silman I: The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix. EMBO J. 2004 Nov 10;23(22):4394-405. Epub 2004 Nov 4.</reference_text>
      <pubmed_id>15526038</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bartels CF, Zelinski T, Lockridge O: Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet. 1993 May;52(5):928-36.</reference_text>
      <pubmed_id>8488842</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Lim LY, Go ML: The anticholinesterase activity of mefloquine.  Clin Exp Pharmacol Physiol. 1985 Sep-Oct;12(5):527-31.</reference_text>
        <pubmed_id>3878759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Davis KL: Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. Geriatrics. 1999 Feb;54(2):42-7; quiz 48.</reference_text>
        <pubmed_id>10024872</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Wang H, Carlier PR, Ho WL, Wu DC, Lee NT, Li CP, Pang YP, Han YF: Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE.  Neuroreport. 1999 Mar 17;10(4):789-93.</reference_text>
        <pubmed_id>10208549</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Traykov L, Tavitian B, Jobert A, Boller F, Forette F, Crouzel C, Di Giamberardino L, Pappata S: In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects. Eur J Neurol. 1999 May;6(3):273-8.</reference_text>
        <pubmed_id>10210906</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Wang H, Tang XC: Anticholinesterase effects of huperzine A, E2020, and tacrine in rats.  Zhongguo Yao Li Xue Bao. 1998 Jan;19(1):27-30.</reference_text>
        <pubmed_id>10375753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Kosasa T, Kuriya Y, Matsui K, Yamanishi Y: Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol. 1999 Sep 10;380(2-3):101-7.</reference_text>
        <pubmed_id>10513568</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Takatori Y: [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease]. Yakugaku Zasshi. 2006 Aug;126(8):607-16.</reference_text>
        <pubmed_id>16880719</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Du DM, Carlier PR: Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr Pharm Des. 2004;10(25):3141-56.</reference_text>
        <pubmed_id>15544504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Krustev AD, Argirova MD, Getova DP, Turiiski VI, Prissadova NA: Calcium-independent tacrine-induced relaxation of rat gastric corpus smooth muscles. Can J Physiol Pharmacol. 2006 Nov;84(11):1133-8.</reference_text>
        <pubmed_id>17218977</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Villarroya M, Garcia AG, Marco JL: New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. Curr Pharm Des. 2004;10(25):3177-84.</reference_text>
        <pubmed_id>15544507</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Marco JL, Carreiras MC: Recent developments in the synthesis of acetylcholinesterase inhibitors.  Mini Rev Med Chem. 2003 Sep;3(6):518-24.</reference_text>
        <pubmed_id>12871155</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Ahmed M, Rocha JB, Correa M, Mazzanti CM, Zanin RF, Morsch AL, Morsch VM, Schetinger MR: Inhibition of two different cholinesterases by tacrine.  Chem Biol Interact. 2006 Aug 25;162(2):165-71. Epub 2006 Jun 17.</reference_text>
        <pubmed_id>16860785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Radic Z, Taylor P: The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7.</reference_text>
        <pubmed_id>10421444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Radic Z, Taylor P: Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4.</reference_text>
        <pubmed_id>11920914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Robaire B, Kato G: Effects of edrophonium, eserine, decamethonium, d-tubocurarine, and gallamine on the kinetics of membrane-bound and solubilized eel acetylcholinesterase. Mol Pharmacol. 1975 Nov;11(6):722-34.</reference_text>
        <pubmed_id>1207670</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Seto Y, Shinohara T: Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch Toxicol. 1988 Aug;62(1):37-40.</reference_text>
        <pubmed_id>3190453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Bourgeois JP, Betz H, Changuex JP: [Effects of chronic paralysis of chick embryo by flaxedil on the development of the neuromuscular junction]. C R Acad Sci Hebd Seances Acad Sci D. 1978 Mar 13;286(10):773-6.</reference_text>
        <pubmed_id>417864</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gallamine Triethiodide</name>
        <accession>HMDB14626</accession>
      </metabolite>
      <reference>
        <reference_text>Elsinghorst PW, Cieslik JS, Mohr K, Trankle C, Gutschow M: First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor. J Med Chem. 2007 Nov 15;50(23):5685-95. Epub 2007 Oct 18.</reference_text>
        <pubmed_id>17944454</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Drake-Baumann R, Seil FJ: Effects of exposure to low-dose pyridostigmine on neuromuscular junctions in vitro. Muscle Nerve. 1999 Jun;22(6):696-703.</reference_text>
        <pubmed_id>10366222</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Ricordel I, Meunier J: [Chemical weapons: antidotes. View about the real means, perspectives].  Ann Pharm Fr. 2000 Jan;58(1):5-12.</reference_text>
        <pubmed_id>10669805</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Prasad V, Scotch R, Chaudhuri AR, Walss C, Fathy DB, Miller C, Luduena RF: Interactions of bovine brain tubulin with pyridostigmine bromide and N,N'-diethyl-m-toluamide. Neurochem Res. 2000 Jan;25(1):19-25.</reference_text>
        <pubmed_id>10685600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Sinton CM, Fitch TE, Petty F, Haley RW: Stressful manipulations that elevate corticosterone reduce blood-brain barrier permeability to pyridostigmine in the Rat. Toxicol Appl Pharmacol. 2000 May 15;165(1):99-105.</reference_text>
        <pubmed_id>10814558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Servatius RJ, Ottenweller JE, Guo W, Beldowicz D, Zhu G, Natelson BH: Effects of inescapable stress and treatment with pyridostigmine bromide on plasma butyrylcholinesterase and the acoustic startle response in rats. Physiol Behav. 2000 May;69(3):239-46.</reference_text>
        <pubmed_id>10869589</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Tonkopii VD, Prozorovskii VB, Suslova IM: [Interaction of reversible inhibitors with the catalytic centers and allosteric sites of cholinesterases]. Biull Eksp Biol Med. 1976 Aug;82(8):947-50.</reference_text>
        <pubmed_id>1026294</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6.</reference_text>
        <pubmed_id>10606746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Guillou C, Mary A, Renko DZ, Gras E, Thal C: Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett. 2000 Apr 3;10(7):637-9.</reference_text>
        <pubmed_id>10762042</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Blesa R: Galantamine: therapeutic effects beyond cognition.  Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34.</reference_text>
        <pubmed_id>10971049</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.</reference_text>
        <pubmed_id>11078030</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76.</reference_text>
        <pubmed_id>12177686</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Olin J, Schneider L: Galantamine for Alzheimer's disease.  Cochrane Database Syst Rev. 2002;(3):CD001747.</reference_text>
        <pubmed_id>12137632</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease.  Drugs. 2000 Nov;60(5):1095-122.</reference_text>
        <pubmed_id>11129124</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease.  Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27.</reference_text>
        <pubmed_id>10971048</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype.  CNS Drug Rev. 2002 Winter;8(4):405-26.</reference_text>
        <pubmed_id>12481195</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T:</reference_text>
        <pubmed_id>20480924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Malatova Z, Gottlieb M, Marsala J: Depression of acetylcholinesterase synthesis following transient cerebral ischemia in rat: pharmacohistochemical and biochemical investigation. Gen Physiol Biophys. 1999 Mar;18(1):57-71.</reference_text>
        <pubmed_id>10378121</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Quistad GB, Zhang N, Sparks SE, Casida JE: Phosphoacetylcholinesterase: toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid. Chem Res Toxicol. 2000 Jul;13(7):652-7.</reference_text>
        <pubmed_id>10898598</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>da Costa VL Jr, Lapa AJ, Godinho RO: Short- and long-term influences of calcitonin gene-related peptide on the synthesis of acetylcholinesterase in mammalian myotubes. Br J Pharmacol. 2001 May;133(2):229-36.</reference_text>
        <pubmed_id>11350858</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S: Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.</reference_text>
        <pubmed_id>12837382</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Ashani Y, Gentry MK, Doctor BP: Differences in conformational stability between native and phosphorylated acetylcholinesterase as evidenced by a monoclonal antibody. Biochemistry. 1990 Mar 13;29(10):2456-63.</reference_text>
        <pubmed_id>1692236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoflurophate</name>
        <accession>HMDB14815</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Jokanovic M, Prostran M: Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem. 2009;16(17):2177-88.</reference_text>
        <pubmed_id>19519385</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Kovacic P: Mechanism of organophosphates (nerve gases and pesticides) and antidotes: electron transfer and oxidative stress. Curr Med Chem. 2003 Dec;10(24):2705-9.</reference_text>
        <pubmed_id>14529460</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Jokanovic M: Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol Lett. 2009 Oct 28;190(2):107-15. Epub 2009 Aug 3.</reference_text>
        <pubmed_id>19651196</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pralidoxime</name>
        <accession>HMDB14871</accession>
      </metabolite>
      <reference>
        <reference_text>Wong L, Radic Z, Bruggemann RJ, Hosea N, Berman HA, Taylor P: Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis. Biochemistry. 2000 May 16;39(19):5750-7.</reference_text>
        <pubmed_id>10801325</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minaprine</name>
        <accession>HMDB14943</accession>
      </metabolite>
      <reference>
        <reference_text>Duarte CD, Barreiro EJ, Fraga CA: Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.</reference_text>
        <pubmed_id>18045214</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minaprine</name>
        <accession>HMDB14943</accession>
      </metabolite>
      <reference>
        <reference_text>Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG: Aminopyridazines as acetylcholinesterase inhibitors.  J Med Chem. 1999 Feb 25;42(4):730-41.</reference_text>
        <pubmed_id>10052979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Davis KL: Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. Geriatrics. 1999 Feb;54(2):42-7; quiz 48.</reference_text>
        <pubmed_id>10024872</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Kryger G, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure. 1999 Mar 15;7(3):297-307.</reference_text>
        <pubmed_id>10368299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Shepherd G, Klein-Schwartz W, Edwards R: Donepezil overdose: a tenfold dosing error.  Ann Pharmacother. 1999 Jul-Aug;33(7-8):812-5.</reference_text>
        <pubmed_id>10466911</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Kosasa T, Kuriya Y, Matsui K, Yamanishi Y: Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol. 1999 Sep 10;380(2-3):101-7.</reference_text>
        <pubmed_id>10513568</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy. 2000 Jan;20(1):1-12.</reference_text>
        <pubmed_id>10641971</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer's disease.  Chem Rec. 2001;1(1):63-73.</reference_text>
        <pubmed_id>11893059</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Ki YS, Park EY, Lee HW, Oh MS, Cho YW, Kwon YK, Moon JH, Lee KT: Donepezil, a potent acetylcholinesterase inhibitor, induces caspase-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull. 2010;33(6):1054-9.</reference_text>
        <pubmed_id>20522977</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Repantis D, Laisney O, Heuser I: Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Jun;61(6):473-81. Epub 2010 Mar 1.</reference_text>
        <pubmed_id>20193764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Demecarium</name>
        <accession>HMDB15079</accession>
      </metabolite>
      <reference>
        <reference_text>Ward DA, Abney K, Oliver JW: The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.</reference_text>
        <pubmed_id>12641839</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Demecarium</name>
        <accession>HMDB15079</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Nguyen PV, Aniksztejn L, Catarsi S, Drapeau P: Maturation of neuromuscular transmission during early development in zebrafish.  J Neurophysiol. 1999 Jun;81(6):2852-61.</reference_text>
        <pubmed_id>10368402</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O: Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology. 1999 Jun 15;134(2-3):169-78.</reference_text>
        <pubmed_id>10403635</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Blasina MF, Faria AC, Gardino PF, Hokoc JN, Almeida OM, de Mello FG, Arruti C, Dajas F: Evidence for a noncholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin. Cell Tissue Res. 2000 Feb;299(2):173-84.</reference_text>
        <pubmed_id>10741458</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Monnet-Tschudi F, Zurich MG, Schilter B, Costa LG, Honegger P: Maturation-dependent effects of chlorpyrifos and parathion and their oxygen analogs on acetylcholinesterase and neuronal and glial markers in aggregating brain cell cultures. Toxicol Appl Pharmacol. 2000 Jun 15;165(3):175-83.</reference_text>
        <pubmed_id>10873710</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Bolognesi ML, Andrisano V, Bartolini M, Minarini A, Rosini M, Tumiatti V, Melchiorre C: Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors.  J Med Chem. 2001 Jan 4;44(1):105-9.</reference_text>
        <pubmed_id>11141093</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Physostigmine</name>
        <accession>HMDB15116</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WC, Ebert MH: Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999 Dec;19(6):513-21.</reference_text>
        <pubmed_id>10587286</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Goldblum D, Garweg JG, Bohnke M: Topical rivastigmine, a selective acetylcholinesterase inhibitor, lowers intraocular pressure in rabbits. J Ocul Pharmacol Ther. 2000 Feb;16(1):29-35.</reference_text>
        <pubmed_id>10673128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J: Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry. 2000 Mar;15(3):242-7.</reference_text>
        <pubmed_id>10713582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1.</reference_text>
        <pubmed_id>11078030</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Gottwald MD, Rozanski RI: Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999 Oct;8(10):1673-1682.</reference_text>
        <pubmed_id>11139819</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE: Rivastigmine for Alzheimer's disease.  Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191.</reference_text>
        <pubmed_id>19370562</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009;12(1):79-85.</reference_text>
        <pubmed_id>19470293</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Lalli S, Albanese A: Rivastigmine in Parkinson's disease dementia.  Expert Rev Neurother. 2008 Aug;8(8):1181-8.</reference_text>
        <pubmed_id>18671661</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Onor ML, Trevisiol M, Aguglia E: Rivastigmine in the treatment of Alzheimer's disease: an update.  Clin Interv Aging. 2007;2(1):17-32.</reference_text>
        <pubmed_id>18044073</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Farlow MR: Update on rivastigmine.  Neurologist. 2003 Sep;9(5):230-4.</reference_text>
        <pubmed_id>14587496</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.  Int Psychogeriatr. 2002;14 Suppl 1:77-91.</reference_text>
        <pubmed_id>12636181</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Ravelli RB, Raves ML, Ren Z, Bourgeois D, Roth M, Kroon J, Silman I, Sussman JL: Static Laue diffraction studies on acetylcholinesterase.  Acta Crystallogr D Biol Crystallogr. 1998 Nov 1;54(Pt 6 Pt 2):1359-66.</reference_text>
        <pubmed_id>10089512</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Keymer JE, Gaete J, Kameid G, Alvarez J: Acetylcholinesterase and inhibitors: effects upon normal and regenerating nerves of the rat. Eur J Neurosci. 1999 Mar;11(3):1049-57.</reference_text>
        <pubmed_id>10103097</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Huby F, Mallet S, Hoste H: Role of acetylcholinesterase (AChE) secreted by parasitic nematodes on the growth of the cell line from epithelial origin HT29-D4. Parasitology. 1999 May;118 ( Pt 5):489-98.</reference_text>
        <pubmed_id>10363282</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Luo C, Saxena A, Ashani Y, Leader H, Radic Z, Taylor P, Doctor BP: Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime. Chem Biol Interact. 1999 May 14;119-120:129-35.</reference_text>
        <pubmed_id>10421446</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Luo C, Saxena A, Smith M, Garcia G, Radic Z, Taylor P, Doctor BP: Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium. Biochemistry. 1999 Aug 3;38(31):9937-47.</reference_text>
        <pubmed_id>10433700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edrophonium</name>
        <accession>HMDB15145</accession>
      </metabolite>
      <reference>
        <reference_text>Martin-Biosca Y, Asensi-Bernardi L, Villanueva-Camanas RM, Sagrado S, Medina-Hernandez MJ: Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.</reference_text>
        <pubmed_id>19472276</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Lockhart B, Closier M, Howard K, Steward C, Lestage P: Differential inhibition of [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):429-38.</reference_text>
        <pubmed_id>11330337</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Hodge AS, Humphrey DR, Rosenberry TL: Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol. 1992 May;41(5):937-42.</reference_text>
        <pubmed_id>1588924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Papp MI, Komoly S, Szirmai IG, Kovacs T: Similarities between CSF-brain extracellular transfer and neurofibrillary tangle invasion in Alzheimer's disease. Neurobiol Aging. 2006 Mar;27(3):402-12. Epub 2005 Jun 27.</reference_text>
        <pubmed_id>15982786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Kenakin TP, Beek D: Self-cancellation of drug properties as a mode of organ selectivity: the antimuscarinic effects of ambenonium. J Pharmacol Exp Ther. 1985 Mar;232(3):732-40.</reference_text>
        <pubmed_id>2857786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Webb GD: Affinity of benzoquinonium and ambenonium derivatives for the acetylcholine receptor, tested on the electroplax, and for acetylcholinesterase in solution. Biochim Biophys Acta. 1965 May 25;102(1):172-84.</reference_text>
        <pubmed_id>5833399</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Bolognesi ML, Cavalli A, Andrisano V, Bartolini M, Banzi R, Antonello A, Rosini M, Melchiorre C: Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Farmaco. 2003 Sep;58(9):917-28.</reference_text>
        <pubmed_id>13679187</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ambenonium</name>
        <accession>HMDB15254</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Radic Z, Taylor P: The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7.</reference_text>
        <pubmed_id>10421444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Golicnik M, Fournier D, Stojan J: Acceleration of Drosophila melanogaster acetylcholinesterase methanesulfonylation: peripheral ligand D-tubocurarine enhances the affinity for small methanesulfonylfluoride. Chem Biol Interact. 2002 Feb 20;139(2):145-57.</reference_text>
        <pubmed_id>11823003</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Radic Z, Taylor P: Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4.</reference_text>
        <pubmed_id>11920914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta RC, Dettbarn WD: Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. Neurotoxicology. 1992 Fall;13(3):649-61.</reference_text>
        <pubmed_id>1475066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tubocurarine</name>
        <accession>HMDB15330</accession>
      </metabolite>
      <reference>
        <reference_text>Bianchi DA, Hirschmann GS, Theoduloz C, Bracca AB, Kaufman TS: Synthesis of tricyclic analogs of stephaoxocanidine and their evaluation as acetylcholinesterase inhibitors. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2711-5.</reference_text>
        <pubmed_id>15878275</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Robaire B, Kato G: Effects of edrophonium, eserine, decamethonium, d-tubocurarine, and gallamine on the kinetics of membrane-bound and solubilized eel acetylcholinesterase. Mol Pharmacol. 1975 Nov;11(6):722-34.</reference_text>
        <pubmed_id>1207670</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Sinha BK, Chignell CF: Synthesis and biological activity of spin-labeled analogs of biotin, hexamethonium, decamethonium, dichlorisoproterenol, and propranolol. J Med Chem. 1975 Jul;18(7):669-73.</reference_text>
        <pubmed_id>239236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Wu CS, Yang JT: Tacrine protection of acetylcholinesterase from inactivation by diisopropylfluorophosphate: a circular dichroism study. Mol Pharmacol. 1989 Jan;35(1):85-92.</reference_text>
        <pubmed_id>2913485</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Seto Y, Shinohara T: Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch Toxicol. 1988 Aug;62(1):37-40.</reference_text>
        <pubmed_id>3190453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Decamethonium</name>
        <accession>HMDB15375</accession>
      </metabolite>
      <reference>
        <reference_text>Hallek M, Szinicz L: Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro. Biochem Pharmacol. 1988 Mar 1;37(5):819-25.</reference_text>
        <pubmed_id>3345199</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Singh AK, Spassova D: Effects of hexamethonium, phenothiazines, propranolol and ephedrine on acetylcholinesterase carbamylation by physostigmine, aldicarb and carbaryl: interaction between the active site and the functionally distinct peripheral sites in acetylcholinesterase. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Jan;119(1):97-105.</reference_text>
        <pubmed_id>9568379</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Trevisani GT, Hyman NH, Church JM: Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction.  Dis Colon Rectum. 2000 May;43(5):599-603.</reference_text>
        <pubmed_id>10826417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Naves LA, Van der Kloot W: Repetitive nerve stimulation decreases the acetylcholine content of quanta at the frog neuromuscular junction. J Physiol. 2001 May 1;532(Pt 3):637-47.</reference_text>
        <pubmed_id>11313435</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Takeuchi K, Kawauchi S, Araki H, Ueki S, Furukawa O: Stimulation by nizatidine, a histamine H(2)-receptor antagonist, of duodenal HCO(3)(-)secretion in rats:relation to anti-cholinesterase activity. World J Gastroenterol. 2000 Oct;6(5):651-658.</reference_text>
        <pubmed_id>11819669</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Minic J, Chatonnet A, Krejci E, Molgo J: Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Br J Pharmacol. 2003 Jan;138(1):177-87.</reference_text>
        <pubmed_id>12522088</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Beck KD, Brennan FX, Moldow RL, Ottenweller JE, Zhu G, Servatius RJ: Stress interacts with peripheral cholinesterase inhibitors to cause central nervous system effects. Life Sci. 2003 May 23;73(1):41-51.</reference_text>
        <pubmed_id>12726885</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang B, Hepner DL, Tran MH, Friedman M, Korn JR, Menzin J: Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.</reference_text>
        <pubmed_id>19257799</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Fucose</name>
        <accession>HMDB00174</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Fucose</name>
        <accession>HMDB00174</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Fucose</name>
        <accession>HMDB00174</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
